184 related articles for article (PubMed ID: 35733364)
1. Serious arrhythmia in initiators of citalopram, escitalopram, and other selective serotonin reuptake inhibitors: A population-based cohort study in older adults.
Aakjaer M; Werther SK; De Bruin ML; Andersen M
Clin Transl Sci; 2022 Sep; 15(9):2105-2115. PubMed ID: 35733364
[TBL] [Abstract][Full Text] [Related]
2. Selective Serotonin Reuptake Inhibitor Use and Risk of Arrhythmia: A Nationwide, Population-Based Cohort Study.
Lin YT; Lu TS; Hansen RA; Wang CC
Clin Ther; 2019 Jun; 41(6):1128-1138.e8. PubMed ID: 31178037
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of QT prolongation with serotonin reuptake inhibitors.
Ojero-Senard A; Benevent J; Bondon-Guitton E; Durrieu G; Chebane L; Araujo M; Montastruc F; Montastruc JL
Psychopharmacology (Berl); 2017 Oct; 234(20):3075-3081. PubMed ID: 28770276
[TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitors may enhance the risk of citalopram- and escitalopram-associated sudden cardiac death among patients receiving hemodialysis.
Assimon MM; Pun PH; Al-Khatib SM; Brookhart MA; Gaynes BN; Winkelmayer WC; Flythe JE
Pharmacoepidemiol Drug Saf; 2022 Jun; 31(6):670-679. PubMed ID: 35285107
[TBL] [Abstract][Full Text] [Related]
5. High-Dose Citalopram and Escitalopram and the Risk of Out-of-Hospital Death.
Ray WA; Chung CP; Murray KT; Hall K; Stein CM
J Clin Psychiatry; 2017 Feb; 78(2):190-195. PubMed ID: 27736049
[TBL] [Abstract][Full Text] [Related]
6. [Citalopram, escitalopram and prolonged QT: warning or alarm?].
Alvarez E; Vieira S; Garcia-Moll X
Rev Psiquiatr Salud Ment; 2014; 7(3):147-50. PubMed ID: 24556340
[TBL] [Abstract][Full Text] [Related]
7. Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis.
Assimon MM; Brookhart MA; Flythe JE
J Am Soc Nephrol; 2019 Apr; 30(4):611-623. PubMed ID: 30885935
[TBL] [Abstract][Full Text] [Related]
8. Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting.
Crépeau-Gendron G; Brown HK; Shorey C; Madan R; Szabuniewicz C; Koh S; Veinish S; Mah L
J Affect Disord; 2019 May; 250():341-345. PubMed ID: 30877856
[TBL] [Abstract][Full Text] [Related]
9. Risk of Ventricular Arrhythmia with Citalopram and Escitalopram: A Population-Based Study.
Qirjazi E; McArthur E; Nash DM; Dixon SN; Weir MA; Vasudev A; Jandoc R; Gula LJ; Oliver MJ; Wald R; Garg AX
PLoS One; 2016; 11(8):e0160768. PubMed ID: 27513855
[TBL] [Abstract][Full Text] [Related]
10. A question about the potential cardiac toxicity of escitalopram.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2012 Apr; 50(4):17-20. PubMed ID: 22421011
[TBL] [Abstract][Full Text] [Related]
11. Investigation of the potential association between the use of fluoxetine and occurrence of acute pancreatitis: a Danish register-based cohort study.
Aakjær M; Kristiansen SB; Pape K; Sessa M; Dalhoff KP; De Bruin ML; Andersen M
Int J Epidemiol; 2022 Oct; 51(5):1656-1665. PubMed ID: 35472246
[TBL] [Abstract][Full Text] [Related]
12. A comparative analysis of selective serotonin reuptake inhibitors and fall risk in older adults.
Haddad YK; Kakara R; Marcum ZA
J Am Geriatr Soc; 2022 May; 70(5):1450-1460. PubMed ID: 35132611
[TBL] [Abstract][Full Text] [Related]
13. Increased Odds of Ventricular Arrhythmias Associated with Selective Serotonin Reuptake Inhibitor Use among the Pediatric and Young Adult Population: A Case-Control Study.
Czaja AS; Anderson HD; Ghosh D; Davidson J; Campbell JD; Valuck RJ
J Pediatr; 2020 Nov; 226():173-178.e8. PubMed ID: 32645405
[TBL] [Abstract][Full Text] [Related]
14. Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: the population-based Rotterdam Study.
Maljuric NM; Noordam R; Aarts N; Niemeijer MN; van den Berg ME; Hofman A; Kors JA; Stricker BH; Visser LE
Br J Clin Pharmacol; 2015 Oct; 80(4):698-705. PubMed ID: 25966843
[TBL] [Abstract][Full Text] [Related]
15. [Citalopram and QT prolongation].
Alušík Š; Paluch Z
Vnitr Lek; 2018; 63(12):952-956. PubMed ID: 29334745
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
Kennedy SH; Andersen HF; Lam RW
J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
[TBL] [Abstract][Full Text] [Related]
17. [Mechanisms of action of antidepressants: new data from Escitalopram].
Fabre V; Hamon M
Encephale; 2003; 29(3 Pt 1):259-65. PubMed ID: 12876551
[TBL] [Abstract][Full Text] [Related]
18. CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation.
Kumar Y; Kung S; Shinozaki G
J Psychopharmacol; 2014 Dec; 28(12):1143-8. PubMed ID: 25122046
[TBL] [Abstract][Full Text] [Related]
19. Effect of date of drug marketing on disproportionality measures in pharmacovigilance: the example of suicide with SSRIs using data from the UK MHRA.
Pariente A; Daveluy A; Laribière-Bénard A; Miremont-Salame G; Begaud B; Moore N
Drug Saf; 2009; 32(5):441-7. PubMed ID: 19419238
[TBL] [Abstract][Full Text] [Related]
20. Comparative safety of selective serotonin reuptake inhibitors among pediatric users with respect to adverse cardiac events.
Czaja AS; Valuck RJ; Anderson HD
Pharmacoepidemiol Drug Saf; 2013 Jun; 22(6):607-14. PubMed ID: 23456956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]